• 604 Citations
  • 12 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Se Hyun Kim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 27 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
eribulin Medicine & Life Sciences
Survival Medicine & Life Sciences
Stomach Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1996 2019

  • 604 Citations
  • 12 h-Index
  • 62 Article

Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors

Kim, S. H., Kim, J. W., Hwang, I. G., Jang, J. S., Hong, S., Kim, T-Y., Baek, J. Y., Shin, S. H., Sun, D. S., Hong, D. S., Kim, H. J., Hong, Y. S., Woo, I. S., Lee, J. H. & Kim, J. H., 1 Sep 2019, In : Journal of Geriatric Oncology. 10, 5, p. 749-756 8 p.

Research output: Contribution to journalArticleResearchpeer-review

C-Reactive Protein
Stomach Neoplasms
Clinical Trials
Propensity Score
Drug Therapy

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Kim, J. Y., Park, S., Im, S-A., Kim, S. B., Sohn, J., Lee, K. S., Chae, Y. S., Lee, K. H., Kim, J. H., Im, Y. H., Kim, T-Y., Lee, K-H., Ahn, J. H., Kim, G. M., Park, I. H., Lee, S. J., Han, H. S., Kim, S. H., Jung, K. H. & Park, Y. H., 28 May 2019, In : Cancer Communications. 39, 1, 29.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Multicenter Studies
Quality of Life
1 Citation (Scopus)

Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients

Kim, H., Kwon, H. J., Han, Y. B., Park, S. Y., Kim, E. S., Kim, S. H., Kim, Y. J., Lee, J-S. & Chung, J-H., 1 Mar 2019, In : Modern Pathology. 32, 3, p. 367-375 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Non-Small Cell Lung Carcinoma
Tumor-Infiltrating Lymphocytes
Tumor Microenvironment
2 Citations (Scopus)
Tumor Microenvironment
Brain Neoplasms
Lung Neoplasms
Neoplasm Metastasis